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C 
lass I MHC-restricted cytotoxic T lymphocytes (CTL) 
have been demonstrated to have potent antiviral activity 
both in vitro and in vivo (1-3). It is therefore not surprising 
that viruses have evolved sophisticated mechanisms to escape 
the effects of CTL. Almost by definition,  a persistent virus 
is one that has evolved some mechanism for avoiding the CTL 
response of the host. In most persistent virus infections, es- 
cape from CTL results in life-long infection of the host with 
some small fraction of the population suffering pathologic 
consequences from the virus infection (4). In HIV infection, 
however, both viral persistence and the devastating conse- 
quences of that infection are the rule, rather than the excep- 
tion. Assuming that escape from CTL plays a role in the ability 
of HIV to maintain persistent infection, it becomes impera- 
tive to better understand this phenomenon and the mecha- 
nisms specifically employed by this virus. In this issue of the 
Journal, Couillin et al.  (5) provide insight into how HIV 
may escape CTL recognition through genetic variation. 
Several lines of evidence suggest that CTL are an impor- 
tant component of the protective immune response to HIV 
infection.  HIV-specific CTL precursors are present at high 
frequency very early during infection, often being detectable 
before seroconversion (6). During the subsequent prolonged 
asymptomatic phase of infection, HIV-specific CD8 + MHC 
class I-restricted CTL activity can routinely be detected directly 
from the peripheral blood in the absence of in vitro stimula- 
tion (7, 8). Limiting dilution analysis has confirmed that a 
high frequency of activated and memory HIV-specific CTL 
are present in the peripheral blood of these patients (9-11). 
However, despite this vigorous CTL response, the virus con- 
tinues to replicate (12, 13). Progression to AIDS is marked 
by an increase in virus replication accompanied by a loss of 
the CD8 + HIV-specific CTL response (11, 14). The associ- 
ation of the CTL response with the initial,  acute decrease 
in viremia and the subsequent loss of that control with progres- 
sion to AIDS strongly implicates the CTL response in con- 
trol of HIV replication  during the asymptomatic phase of 
infection. 
How then might HIV, or any other persistent virus, evade 
the CTL response of the host? On first inspection one might 
assume that a virus would simply escape a CTL response by 
altering the amino acid sequence within the epitope(s) rec- 
ognized by that response. While this may be the most inten- 
sively studied,  it is by no means the only, or the most fre- 
quently used, viral escape  mechanism. Table 1 provides a listing 
of defined and proposed  mechanisms utilized by viruses to 
avoid the CTL response of the host. This commentary will 
not discuss all available  mechanisms, but will concentrate upon 
the role of sequence variation  in CTL escape. 
Sequence variation is thought to affect CTL recognition 
in any one of three ways: blocking correct transport and 
processing of the antigen, blocking peptide binding to the 
MHC molecule, or blocking optimal recognition of the pep- 
tide/MHC complex by the TCR. In the last mechanism, ei- 
ther the peptide/MHC complex will fail to engage the TCR 
(15), or the TCR may be suboptimaUy engaged by the al- 
tered peptide/MHC complex, resulting in a decreased ability 
of that CTL to respond upon encountering a cell that presents 
the peptide/MHC complex to which the CTL was origi- 
nally generated (a phenomenon referred to as "antagonism") 
(16-19). The exact mechanism involved in antagonism, how- 
ever, is still unclear. These escape mechanisms are diagramat- 
ically shown in Fig.  1.  It should be noted that this figure 
does not depict the recently described pathway utilized in 
the processing of some HIV envelope epitopes which is inde- 
pendent of the Tapl/Tap2  transporter complex (20). 
There is evidence, in viral infections other than HIV, for 
all three mechanisms of sequence variation leading to CTL 
escape. Variation in regions surrounding an epitope has been 
shown to lead to nonrecognition by influenza virus-specific 
CTL, though it remains uncertain ffproteolytic cleavage,  trans- 
port, or another step in processing is affected  by the sequence 
changes (21). In addition, lymphocytic choriomeningitis virus 
has been shown to alter sequences within defined epitopes 
as a mechanism of escape both in vitro and in vivo (22, 23). 
It has also recently been shown that EBV sequences recov- 
ered from a population with a high prevalence  of  HLA-A11-ex- 
pressing individuals have an alteration  in a key amino acid 
residue critical for binding of the peptide epitope to the HLA- 
All molecule (24). In addition to changes affecting peptide 
binding to MHC, there is also evidence that variation which 
allows altered peptide ligands to bind MHC may affect TCR 
recognition either directly or by the mechanism of antagonism 
(16-19). 
Several investigators had previously attempted to determine 
whether changes in amino acid sequences  within defined CTL 
epitopes are responsible for the ability of HIV to escape the 
CTL response in vivo (25-29). By looking at sequences  within 
defined epitopes, it has been shown that CTL clones or short- 
term lines from HIV-infected individuals will fail to recog- 
nize some, but not all, strains of HIV (23, 25-28).  Some 
studies compared virus sequences within the patients  from 
whom the CTL lines were derived (25, 29), while in other 
studies virus sequences from a national  database were used 
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Volume 180  September  1994  779-782 Table  1.  Mechanisms  Possibly Used by Viruses to Avoid Recognition by the Host's CTL Response 
Mechanism  Reference 
Viral latency 
Replication  in "immune-privileged"  sites* 
Induction  of immunosuppression* 
Induction  of CTL clonal exhaustion* 
MHC class I downregulation* 
Adhesion  molecule downregulation 
Altered  expression  of specific viral antigens 
Blockage of "lethal  hit" cascade 
Cytokine alterations* 
Amino acid sequence variation* 
Affecting peptide  transport,  cleavage/processing* 
Affecting  MHC binding* 
Affecting  TCR recognition* 
Resulting in antagonism* 
reviewed 4 
reviewed 4 
(33) 
(9) 
(34, 35) 
(36) 
(37) 
$ 
(38) 
(5, 22,  25) 
(5, 21,  39) 
(5, 24) 
(is) 
(16-19) 
* Mechanisms for which there is evidence in HIV infection. 
* Theoretical mechanism lacking evidence in a viral system. 
(26-28).  In none of these studies, however, was the impact 
of the changes on binding to MHC or the impact of changes 
in flanking  sequences directly addressed. 
In the study published in this issue of the Journal, Couillin 
et al.  (5) provide evidence suggesting  in vivo escape from 
CTL  occurs  as  a  result  of alterations  in  anchor  residues 
(affecting  peptide  binding  to  MHC),  nonanchor  residues 
(affecting TCR recognition) and flanking residues (affecting 
transport/processing) of epitopes within HIV nef. The unique 
aspect of this study is that  the ability of autologous virus 
sequences to be recognized by CTL was compared with the 
ability of the peptide epitopes to bind to and  stabilize the 
MHC/32 microglobulin complex. Peptides altered at predicted 
anchor residues were unable to bind MHC and were also not 
recognized by the CTL response. In addition, it was shown 
that there are multiple variable regions of HIV nefthat  are 
potential CTL epitopes and that can escape the CTL response 
as a result of that variability. These studies therefore suggest 
that sequence variation within the genome of HIV may lead 
to nonrecognition  by the CTL response through  a variety 
of mechanisms. 
Having documented  that  variants of HIV which escape 
a defined CTL response do exist within patients, it becomes 
logical to ask if these variants then predominate within the 
viral quasispecies of the patients.  In one study, CTL escape 
variants of HIV were identified in patients, yet these viruses 
did not go on to dominate the viral quasispecies  within those 
patients (25). In a separate study of four patients, no escape 
variants to an HLA-B27-restricted response were identified 
over a 14-mo period (30). In addition, it has also been shown 
that  simian  immunodeficiency  virus  (SIV)-infected  rhesus 
monkeys can progress from initial infection through to AIDS 
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without ever generating a virus that escapes a MaMu-Al-re- 
stricted response to gag (31), indicating that escape from CTL 
is not necessary for either the persistent replication of HIV/SIV, 
nor for the pathologic consequences thereof. On closer in- 
spection,  however, it is apparent  that  these results do not 
necessarily rule out the potential importance of HIV sequence 
variation  in escape from CTL and viral persistence. 
Most of the studies published to date have investigated a 
small  number  of CTL  epitopes present  within  conserved 
regions of the genome,  a result of a reliance on laboratory 
strains  of HIV in the definition of CTL epitopes (25-31). 
In reality, multiple epitopes within conserved and variable 
regions of the HIV genome are probably recognized by the 
CTL response of any given individual (32). The fact that es- 
cape is not observed or does not predominate at a single epi- 
tope does not rule out the possibility that escape is occurring 
in multiple other epitopes. HIV replication in the face of a 
vigorous CTL response is evidence that  the CTL response 
is not 100% ef~cient at controlling HIV. A virus which es- 
capes part of the CTL response may therefore have a significant 
survival advantage over one that does not. In the studies cited 
above, it is possible that sequence variation leading to CTL 
escape occurred within other nonidentified epitopes, or was 
mediated by sequence variation outside of the defined epi- 
topes and led to improper processing. In addition, the recent 
description of variant CTL epitope antagonism in HIV sug- 
gests that the presence, within a patient, of a small percentage 
of viruses containing altered epitope sequences may be ade- 
quate to block CTL lysis of cells infected with viruses con- 
taining  wild-type sequences (18).  This would suggest that 
escape variants may not necessarily become the predominant 
viral species since they will also confer a survival advantage /  -, 
viral 
antigen 
HC-! 
m 
"::"  U  '  U  U 
non-recognition  sub-optimal recognition  recognition 
(antagonism) 
to viruses that do not contain the escape variant sequences. 
Based upon the work published in this issue of the Journal, 
and  that  of others,  it is safe to say that  sequence variation 
resulting  in escape from certain CTL responses does occur 
in HIV infection,  and  that multiple mechanisms  are prob- 
ably involved. The relevance of these findings,  however, re- 
mains  to be  determined.  Further  work  along  the  lines  of 
Couillin  et al.  (5),  in which both MHC  binding and CTL 
recognition of autologous virus sequences are assessed, may 
help provide insight into the dynamic interplay which exists 
between  HIV  and  the  CTL response  to  this  pathogen. 
Figure  1.  Diagrammatic representation of how amino acid sequence 
variation can affect  antigen processing, presentation, and recognition. Open 
circles represent a nine amino acid CTL epitope which, when processed 
and presented, is recognized by a TCR. Flanking amino acids are shown 
as darkened circles. Altered amino acids are shown as pointed circles. If 
the flanking amino acids are altered, the epitope is not cleaved/trans- 
ported/processed into the endoplasmic reticulum/golgi complex. If an an- 
chor residue is altered (shown as an amino acid that binds into a deep 
pocket in the MHC molecule), transport and processing may occur, but 
binding to the MHC molecule  does not occur and a stable  Peptide/MHC/32 
microglobulin (32-m) complex is not formed. If a nonanchor residue is 
altered, binding to, and stabilization of, the MHC/32-m complex may 
occur, followed by transport of the complex to the cell surface. The TCR 
may then either not engage the peptide/MHC complex or it may subop- 
timally engage the complex, leading to the phenomenon of antagonism. 
The author thanks D. D.  Ho, B. D.  Walker, and C.  A.  Andrews  for helpful discussions. 
This work was supported by grants AI-30358 and AI-35522 from the National Institutes of Health. 
Address correspondence to Dr. R. A. Koup, Aaron Diamond AIDS Research Center, 455 First Avenue, 
7th Floor, New York,  NY  10016. 
R.ef'el"ences 
1.  Tsubota, H., C.I. Lord, D.I. Watkins, C. Morimoto, and N.L. 
Letvin. 1989. A cytotoxic T lymphocyte inhibits acquired im- 
munodeficiency syndrome virus replication in peripheral blood 
lymphocytes. J. Exp. Ailed. 169:1421. 
2.  Lukacher, A.E., V.L. Braciale, and T.J. Braciale.  1984. In vivo 
effector function of influenza virus-specific cytotoxic T lym- 
phocytes clones is highly specific, j. Exp. Med.  160:814. 
3.  Byrne, J.A., and M.B.A. Oldstone.  1984.  Biology of cloned 
cytotoxic T lymphocytes specific for lymphocytic choriomen- 
ingitis virus: clearance of virus in vivo. J.  Virol. 51:682. 
4.  Ahmed, R., andJ.G. Stevens. 1990. Viral Persistence. In Viro- 
logy. B.N. Fields and D.M. Knipe, editors. Raven Press, Ltd., 
New York.  241-265. 
5.  Couillin,  I., B. Culmann-Penciolelli,  E. Gomard, J.-P. Levy, 
J.-G. Guillet, and S. Saragosti. 1994. Impaired CTL recogni- 
tion due to genetic variations in the main immunogenic re- 
gion of the HIV-1 nef protein. J. Exp. Med.  180:1129. 
6.  Koup, R.A., J.T. Safrit, Y. Cao, C.A. Andrews, G. McLeod, 
781  Koup 
W. Borkowsky, C. Farthing,  and D.D. Ho. 1994.  Temporal 
association of cellular immune responses with the initial con- 
trol of viremia in primary HIV-1 syndrome.J. Virol. 68:4650. 
7.  Walker,  B.D., S. Chakrabarti, B. Moss, T.J. Paradis, T. Flynn, 
A.G. Dumo, R.S. Blumberg, J.C. Kaplan, M.S. Hirsch, and 
R.T. Schooley.  1987. HIV-specific cytotoxic T lymphocytes in 
seropositive individuals. Nature (Lond.). 328:345. 
8.  Koup, R.A., J.L. Sullivan,  P.H. Levine, D. Brettler, A. Mahr, 
G. Mazzara, S. McKenzie, and D. Panicali.  1989.  Detection 
of major histocompatibility complex class 1-restricted, HIV- 
specific  cytotoxic T  lymphocytes in  the  blood  of infected 
hemophiliacs. Blood. 73:1909. 
9.  Gotch, F.M., D.F. Nixon, N. Alp, A.J. McMichael, and L.K. 
Borysiewicz.  1990.  High frequency of memory and effector 
gag specific cytotoxic T lymphocytes in HIV seropositive in- 
dividuals. Int. Immunol.  2:707. 
10.  Koup, R.A., C.A. Pikora, K. Luzuriaga, D.B.  Brettler, E.S. 
Day, G.P. Mazzara, and J.L. Sullivan.  1991. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency 
virus gag antigens in infected persons: in vitro quantitation 
of effector cell populations with p17 and p24 specificities, j. 
Exp. Med.  174:1593. 
11.  Carmichael, A., X. Jin, P. Sissons, and L. Borysiewicz. 1993. 
Quantitative analysis of the human immunodeficiency virus 
type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response 
at different stages of HIV-1 infection: differential CTI, responses 
to HIV-1  and Epstein Barr virus in late disease, j. Exp. Med. 
177:249. 
12.  Ho, D.D., T. Moudgil, and M. Alam. 1989. Quantitation of 
human immunodeficiency virus type 1 in the blood of infected 
persons.  N. Engl. J. Med.  321:1621. 
13.  Piatak, M.J., M.S.  Saag, L.C. Yang, S.J. Clark, J.C. Kappes, 
K=C. Luk, B.H. Hahn,  G.M. Shaw,  and J.D.  Lifson. 1993. 
High levels of HIV-1 in plasma during all stages of infection 
determined by competitive PCR. Science (Wash. DC). 259:1749. 
14.  Connor, R.I., H. Mohri, Y. Cao, and D.D. Ho. 1993. Increased 
viral  burden  and  cytopathicity  correlate  temporally  with 
CD4 § T-lymphocyte decline and clinical progression in HIV-1 
infected individuals.  J.  Virol. 67:1772. 
15.  Lill, N.L., M.J. Tevethia, W.G. Hendrickson, and S.S. Tevethia. 
1992. Cytotoxic T lymphocytes (CTL) against a transforming 
gene product select for transformed cells with point mutations 
within sequences encoding CTL recognition epitopes.J. Exp. 
Med.  176:449. 
16. Jameson, S.C., F.R.. Carbone, and M.J. Bevan.  1993. Clone- 
specific T cell receptor antagonists of major histocompatibility 
complex class-I-restricted cytotoxic T cells.J. Exp. Med. 177: 
1541. 
17.  Sloan-Lancaster,  J., B.D. Evavold,  and P.M.  Allen.  1993. In- 
duction of T-cell anergy by altered T-cell-receptor ligands  on 
live antigen presenting cells. Nature (Lond.). 363:156. 
18.  Klenerman, P., S. Rowland-Jones, S. McAdams, J. Edwards, 
S. Daenke, D. Lalloo, B. Koppe, W. Rosenberg, D. Boyd, A. 
Edwards, et al. 1994. Cytotoxic T-cell activity antagonized by 
naturally occurring HIV-1 gag variants. Nature (Lond.). 369:403. 
19.  Bertoletti, A.,. A. Sette, F.V. Chisari, A. Penna,  M. Levrero, 
M. De Carli, F. Fiaccadori,  and C. Ferrari. 1994. Natural vari- 
ants of cytotoxic epitopes are T-cell receptor antagonists for 
antiviral cytotoxic T  cells. Nature (Lond.). 369:407. 
20.  Hammond, S.A., R.C. Bollinger,  T.W. Tobery, and R.F. Sili- 
ciano. 1993. Transporter-independent  processing of HIV-1 enve- 
lope for recognition by CD8 § T cells. Nature (Lond.). 364:158. 
21.  Eisenlohr,  L.C.,  J.W.  Yewdell,  and  J.R.  Bennink.  1992. 
Flanking  sequences  influence  the  presentation  of  an  en- 
dogenously synthesized peptide to cytotoxic T lymphocytes. 
J. Exp. Med.  175:481. 
22.  Pircher,  H., D. Moskophidis, U. Rohrer, K. Burki, H. Hen- 
gartner, and R.M.  Zinkernagel.  1990.  Viral escape by selec- 
tion of cytotoxic T cell-resistant virus variants in vivo. Nature 
(Lond.). 346:629. 
23.  Aebischer,  T., D. Moskophidis, U.H. Rohrer, R.M.  Zinker- 
nagel, and H. Hengarmer. 1991. In vitro selection of lympho- 
cytic choriomeningitis virus escape mutants by cytotoxic T lym- 
phocytes. Proc. Natl. Acad. Sci.  USA.  88:11047. 
24.  de Campos-Lima, P.-O., V. Levitsky, J. Brooks, S.P. Lee, L.F. 
Hu, A.B. Rickinson, and M.G. Masucci.  1994. T cell responses 
and virus evolution: loss of HLA All-restricted CTL epitopes 
in Epstein-Barr virus isolates from highly All-positive popu- 
lations by selective mutation at anchor residues. J. Exp. Med. 
179:1297. 
25.  Phillips,  R.E.,  S. Rowland-Jones, D.F.  Nixon, F.M. Gotch, 
J.P.  Edwards,  A.O.  Ogunlesi,  J.A.  Rothbard,  C.R.M. 
Bangham, C.R.  Rizza, and A.J.  McMichael.  1991. Human 
immunodeficiency virus genetic variation that can escape cyto- 
toxic T  cell recognition. Nature (Lond.). 354:453. 
26.  Dai, L.C., K. West, R. Littaua, K. Takahashi, and F.A. Ennis. 
1992. Mutation of the human immunodeficiency virus type 
1 at  amino  acid  585  on gp41  results  in  loss  of killing by 
CD8 § A24-restricted cytotoxic T  lymphocytes. J.  Virol. 66: 
3151. 
27.  Johnson, R.P., A. Trocha, T.M. Buchanan, and B.D. Walker. 
1992. Identification  of overlapping HLA class I-restricted cyto- 
toxic T cell epitopes in a conserved region of the human im- 
munodeficiency virus type 1 envelope glycoprotein: definition 
of minimum epitopes and analysis of the effects of sequence 
variation. J. Exp.  Med.  175:961. 
28.  Johnson, R.P., A. Trocha, T.M. Buchanan, and B.D. Walker. 
1993. Recognition of a highly conserved region of human im- 
munodeficiency virus type 1 gpl20 by an HLA-Cw4-restricted 
cytotoxic T-lymphocyte clone. J.  Virol. 67:438. 
29.  Safrit, J.T., C.A. Andrews, T. Zhu, D.D. Ho, and R.A. Koup. 
1994. Characterization of HIV-l-specific cytotoxic T lymphocyte 
clones isolated during acute seroconversion: recognition of auto- 
logous virus sequences within a conserved immunodominant 
epitope. J. Exp. Med.  179:463. 
30.  Meyerhans,  A.,  G.  Dadaglio, J.-P.  Vartanian,  P.  Langlade- 
Demoyen, R. Frank, B. Asjo, F. Plata,  and S. Wain-Hobson. 
1991.  In  vivo  persistence  of a  HIV-l-encoded  HLA-B27- 
restricted cytotoxic T  lymphocyte epitope despite specific in 
vitro reactivity. Eur. J.  Immunol.  21:2637. 
31.  Chen, Z.W., L. Shen, M.D. Miller, S.H. Ghim, A.L. Hughes, 
and N.L. Letvin. 1992. Cytotoxic T lymphocytes do not ap- 
pear to select for mutations in an immunodominant epitope 
of simian immunodeficiency virus gag.J. Immunol.  149:4060. 
32.  McMichael, A.J., and B.D. Walker.  1994. Cytotoxic T lym- 
phocyte epitopes: implications for HIV vaccines. AIDS: 8(Suppl. 
1):S155. 
33.  Tishon, A., P. Borrow, C. Evans, and M.B.A. Oldstone. 1993. 
Virus-induced immunosuppression 1: Age at infection relates 
to a selective or generalized defect. Virology. 195:397. 
34.  Burgert, H.-G., J.L. Maryanski, and S. Kvist. 1987. E3/19K 
protein of adenovirus type 2 inhibits lysis of cytolytic T lym- 
phocytes by blocking cell-surface expression of histocompati- 
bility class I antigens. Proc. Natl. Acad. Sci. USA.  84:1356. 
35.  Howcroft, T.K., K. Strebel, M.A. Martin,  and D.S. Singer. 
1993. Repression of MHC class I gene promoter activity by 
two-exon tat of HIV. Science (Wash. DC).  260:1320. 
36.  Gregory, C.D., R.J.  Murray, C.F.  Edwards,  and A.B.  Rick- 
inson. 1988. Downregulation of cell adhesion molecules LFA-3 
and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma 
underlies tumor escape from virus-specific T cell surveillance. 
J. Exp.  Med,  167:1811. 
37.  del Val, M., H. Hengel, H. H~icker, U. Hartlaub, T. Ruppert, 
P. Lhcin, and U.H. Koszinowski. 1992. Cytomegalovirus pre- 
vents antigen presentation by blocking the transport ofpeptide- 
loaded major histocompatibility complex class I molecules into 
the medial-Golgi compartment. J. Exp.  Med.  176:729. 
38.  Wold, W.S. 1993. Adenovirus genes that modulate the sensi- 
tivity of virus-infected cells to lysis by TNF. J. Cell. Biochem. 
53:329. 
39.  del Val, M., H.-J. Schlicht, T. Ruppert, M.J. Reddehase,  and 
U.H. Koszinowski. 1991. Efficient processing of an antigenic 
sequence for presentation by MHC class I molecules depends 
on its neighboring residues  in the protein. Cell.  66:1145. 
782  Commentary 